delta-tocotrienol, tocotrienol, delta
| Name | Delta-Tocotrienol | ||
| PubChem CID | 5282350 | ||
| Molecular Weight | 396.6g/mol | ||
| Synonyms |
delta-tocotrienol, tocotrienol, delta |
||
| Formula | C₂₇H₄₀O₂ | ||
| SMILES | CC1=CC(=CC2=C1OC(CC2)(C)CCC=C(C)CCC=C(C)CCC=C(C)C)O | ||
| InChI | 1S/C27H40O2/c1-20(2)10-7-11-21(3)12-8-13-22(4)14-9-16-27(6)17-15-24-19-25(28)18-23(5)26(24)29-27/h10,12,14,18-19,28H,7-9,11,13,15-17H2,1-6H3/b21-12+,22-14+/t27-/m1/s1 | ||
| InChIKey | ODADKLYLWWCHNB-LDYBVBFYSA-N | ||
| CAS Number | 25612-59-3 | ||
| ChEMBL ID | CHEMBL121305 | ||
| ChEBI ID | CHEBI:33276 | ||
| KEGG ID | C14156 | ||
| Structure | 
|
Download
2D
MOL
3D
MOL
|
|
| Chineses Pinyin | HuMaYe | ||
| Use Part | Leaf | ||
| Flavor | Sweet | ||
| Species |
>Kingdom: Viridiplantae
-->Phylum: Streptophyta
-->Class: Equisetopsida
-->Order: Lamiales
-->Family: Pedaliaceae
-->Genus: Sesamum
-->Species: Sesamum indicum
|
||
| Chineses Pinyin | ZongLv | ||
| Use Part | Petiole and fibre of sheath | ||
| Habitat | HuNan, JiangXi, ZheJiang, FuJian, GuangDong, GuiZhou, YunNan, HaiNan, XiZang, TaiWan | ||
| Flavor | Bitter; Astringent | ||
| Meridian Tropism | Lung; Liver; Large Intestine | ||
| Species |
>Kingdom: Viridiplantae
-->Phylum: Streptophyta
-->Class: Equisetopsida
-->Order: Arecales
-->Family: Arecaceae
-->Genus: Trachycarpus
-->Species: Trachycarpus fortunei
|
||
| Pair Name | Delta-Tocotrienol, Cisplatin | |||
| Partner Name | Cisplatin | |||
| Disease Info | [ICD-11: 2C73] | Ovarian cancer | Investigative | |
| Biological Phenomena | Induction-->Blockade of cell cycle in G0/G1 phase | |||
| Gene Regulation | Down-regulation | Expression | CCND1 | hsa595 |
| Down-regulation | Expression | CCND3 | hsa896 | |
| Down-regulation | Expression | CDK4 | hsa1019 | |
| Down-regulation | Expression | CDK6 | hsa1021 | |
| Up-regulation | Expression | PSMD9 | hsa5715 | |
| Up-regulation | Expression | CDKN1A | hsa1026 | |
| Up-regulation | Expression | CYCS | hsa54205 | |
| Up-regulation | Expression | BAX | hsa581 | |
| Down-regulation | Expression | BCL2 | hsa596 | |
| Up-regulation | Cleavage | CASP3 | hsa836 | |
| Up-regulation | Cleavage | CASP9 | hsa842 | |
| Up-regulation | Cleavage | PARP1 | hsa142 | |
| Up-regulation | Phosphorylation | MAPK8 | hsa5599 | |
| Up-regulation | Phosphorylation | MAPK14 | hsa1432 | |
| In Vitro Model | IGROV-1 | Ovarian endometrioid adenocarcinoma | Homo sapiens (Human) | CVCL_1304 |
| SK-OV-3 | Ovarian serous cystadenocarcinoma | Homo sapiens (Human) | CVCL_0532 | |
| IGROV-1/Pt1 | Ovarian endometrioid adenocarcinoma | Homo sapiens (Human) | CVCL_EQ62 | |
| Result | δ-Tocotrienol sensitizes and re-sensitizes ovarian cancer cells to cisplatin via induction of G1 phase cell cycle arrest and ROS/MAPK-mediated apoptosis | |||
| Pair Name | Delta-Tocotrienol, Bortezomib | |||
| Partner Name | Bortezomib | |||
| Disease Info | [ICD-11: 2A00-2F9Z] | Solid tumour or cancer | Investigative | |
| Gene Regulation | Down-regulation | Expression | NFE2L1 | hsa4779 |
| Down-regulation | Expression | PSMA7 | KEGG ID N.A. | |
| Down-regulation | Expression | PSMB7 | KEGG ID N.A. | |
| Down-regulation | Expression | PSMC4 | KEGG ID N.A. | |
| Down-regulation | Expression | POMP | KEGG ID N.A. | |
| In Vitro Model | NCI-H2452 | Pleural biphasic mesothelioma | Homo sapiens (Human) | CVCL_1553 |
| PANC-1 | Pancreatic ductal adenocarcinoma | Homo sapiens (Human) | CVCL_0480 | |
| A-549 | Lung adenocarcinoma | Homo sapiens (Human) | CVCL_0023 | |
| Result | These findings suggested that the inactivation of NFE2L1 by T3, TOS, and T3E is essential to potentiate the cytotoxic effect of the proteasome inhibitor, BTZ, in solid cancers. | |||
| Pair Name | Delta-Tocotrienol, Docetaxel | |||
| Partner Name | Docetaxel | |||
| Disease Info | [ICD-11: 2C82.0] | Prostate cancer | Investigative | |
| Biological Phenomena | Induction-->Necroptosis | |||
| Gene Regulation | Up-regulation | Cleavage | CASP3 | hsa836 |
| Up-regulation | Phosphorylation | RIPK1 | hsa8737 | |
| Up-regulation | Phosphorylation | MLKL | hsa197259 | |
| Down-regulation | Expression | CFLAR | hsa8837 | |
| Up-regulation | Phosphorylation | RIPK1 | hsa8737 | |
| In Vitro Model | DU145 | Prostate carcinoma | Homo sapiens (Human) | CVCL_0105 |
| PC-3 | Prostate carcinoma | Homo sapiens (Human) | CVCL_0035 | |
| Result | The ability of δ-TT to induce necroptotic cell death may represent a promising therapeutical approach to overcome DTX chemoresistance in PCa. | |||
| No. | Title | Href |
|---|---|---|
| 1 | δ-Tocotrienol sensitizes and re-sensitizes ovarian cancer cells to cisplatin via induction of G1 phase cell cycle arrest and ROS/MAPK-mediated apoptosis. Cell Prolif. 2021 Nov;54(11):e13111. doi: 10.1111/cpr.13111. | Click |
| 2 | α-Tocotrienol and Redox-Silent Analogs of Vitamin E Enhances Bortezomib Sensitivity in Solid Cancer Cells through Modulation of NFE2L1. Int J Mol Sci. 2023 May 27;24(11):9382. doi: 10.3390/ijms24119382. | Click |
| 3 | Necroptosis Induced by Delta-Tocotrienol Overcomes Docetaxel Chemoresistance in Prostate Cancer Cells. Int J Mol Sci. 2023 Mar 3;24(5):4923. doi: 10.3390/ijms24054923. | Click |
